The CRISPR Licensing Landscape

@LSPN May 3-4th, 2023, Boston MA

Contact Michael.Arciero@ersgenomics.com for more information.

favicon-300x300

ERS Genomics

ERS is the world leader in licensing CRISPR/Cas9 technology.
 Our founder, Dr. Emmanuelle Charpentier  won the Nobel Prize the discovery of CRISPR/Cas9 in 2020. 

CRISPR/Cas9 has transformed the field of gene editing. 
At ERS, our purpose is to extend global access to this technology and expand the boundaries of CRISPR potential.
 

Michael Arciero, VP IP & Commercial Development with ERS Genomics will speak at this year’s Life Sciences Patent Network (LSPN) in Boston, May 3-4. 

Attend this session to understand:

1. The current CRISPR Licensing Landscape

2. Common misperceptions: Fact vs. Fction

3. The patent batttle – what’s next?

4. Do you need a license?

5. Regional differences – what geolocation means for your licensing requirements.


CRISPR/Cas9 is a patented invention, so any commerical use requires a license. Despite the confusion caused by several high-profile patent interference cases, the patent landscape is clearer than you might think.

Contact Michael.Arciero@ersgenomics.com to secure your CRISPR/Cas9 license.

 

Schedule time with:

Michael Arciero, Vice President IP & Commercial Development

‘This is a lot of misinformation in circulation when it comes to the CRISPR licensing landscape. In speaking at LSPN, my goal is to cut through the noise and provide straightforward answers to common misperceptions.’

Licensing

Intellectual Property

Knowledge Centre

Contact US

Read More Of Our Articles

Explore more news on CRISPR/Cas9 and how it can provide a leading edge in the highly competitive biotech sector.

AI + CRISPR: Powering the 21st Century’s Biological Revolution 

We stand at the forefront of a pivotal moment in human innovation—where AI and CRISPR gene editing converge to power what can only be described as the 21st century’s biological revolution.  A New Industrial Epoch  Just as coal and steam powered the 19th-century Industrial Revolution and electricity and chemistry fuelled.

Read Full Article

Licensee Case Study: Bioneer

Making CRISPR more accessible for scientific innovation   At ERS Genomics, we make CRISPR/Cas9 accessible to innovators. By licensing the foundational IP co-owned by Professor Emmanuelle Charpentier, we enable a broad spectrum of applications outside of direct therapeutic use—from drug discovery to innovation in fields far beyond pharma. One of.

Read Full Article

ERS Genomics and Jumpcode Genomics sign CRISPR/Cas9 license agreement 

License agreement provides Jumpcode Genomics access to CRISPR gene editing technology to enhance next-generation sequencing capabilities    Dublin, Ireland, and San Diego, CA, 27 March, 2025: ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Jumpcode Genomics (‘Jumpcode’), a life science tools company improving and reducing the cost of next-generation.

Read Full Article